ISO 10993 and ISO 14155 2026 Updates: Biocompatibility and Clinical GCP Standards

The April 2026 updates to ISO 10993-6, ISO 10993-7, and ISO 14155 introduce important changes for medical device biocompatibility and clinical investigations. These revised standards reflect modern testing approaches, updated risk-based methodologies, and strengthened clinical good practice requirements. Manufacturers and sponsors must ensure alignment with these new state-of-the-art expectations for regulatory compliance in the EU and beyond.

Updated Biocompatibility Standards: ISO 10993-6:2026 and ISO 10993-7:2026

The revised ISO 10993 series introduces enhanced scientific and methodological updates to support more accurate biological safety evaluation of medical devices.

Enhanced Definitions and Risk-Based Approach

Both standards incorporate updated definitions aligned with current regulatory expectations and scientific understanding. A stronger emphasis is placed on risk-based evaluation, including:

• Patient-Centric Allowable Limits

• Structured risk assessment methodologies

• Improved justification of biological safety thresholds

This ensures more clinically relevant biocompatibility evaluations.

New and Expanded Test Methods

ISO 10993-6:2026 introduces new and refined approaches for evaluating local effects after implantation, including:

• New Annex E addressing peripheral nerve tissue testing

• Expanded Annex G guidance on histopathological evaluation

These additions support more precise and relevant assessment of tissue responses.

Updated Guidance on Ethylene Oxide Residuals

ISO 10993-7:2026 focuses on improving safety assessment for sterilization residues, particularly ethylene oxide (EO). Key enhancements include:

• Expanded Annex F and G guidance on EO residual determination

• Updated methodologies for exposure assessment

• Improved alignment with modern analytical techniques

These updates strengthen patient safety evaluation for sterilized medical devices.

Regulatory Relevance and State-of-the-Art Expectation

Although these ISO updates are not yet formally included in the FDA recognized standards list, they are expected to be adopted soon. As a result, they should already be considered state-of-the-art standards in regulatory submissions and biocompatibility assessments.

ISO 14155:2026 – Clinical Investigation and Good Clinical Practice Update

The fourth edition of ISO 14155 replaces ISO 14155:2020 and introduces immediate application requirements, with no transition period. This makes timely implementation essential for sponsors and clinical investigators.

Reinforced Risk Management Requirements

The updated standard introduces a more structured approach to clinical risk management by distinguishing between:

• Risks related to device use, including residual risks assessed against study design and population

• Risks arising from non-routine clinical procedures required by the clinical investigation plan

The second category now requires a descriptive risk assessment approach, improving consistency in evaluation.

Clinical Event Committees (CEC)

A dedicated framework for Clinical Event Committees is introduced. These independent expert committees, established by sponsors, ensure:

• Consistent event classification across study sites

• Objective assessment of clinical outcomes

• Improved data integrity in multicenter trials

Data Monitoring Committees (DMC)

Sponsors must now formally document DMC responsibilities, including:

• Criteria for study suspension or termination

• Oversight of patient safety during the investigation

• Transparent decision-making processes

This strengthens overall trial governance.

Clinical Investigation Design Enhancements

A new informative Annex K provides guidance on study design, referencing:

• FDA guidance

• MHRA expectations

• ICH E9(R1) statistical principles

This supports more robust and internationally aligned clinical study design.

Adverse Event Reporting Clarifications

The updated standard clarifies sponsor responsibilities for:

• AE collection procedures

• Reporting pathways and timelines

• Consistent classification of clinical events

This improves harmonization of safety reporting practices.

Regulatory Impact for Sponsors and Manufacturers

The ISO 14155:2026 update introduces immediate obligations for clinical trial sponsors. Key impacts include:

• Mandatory update of QMS procedures

• Revision of Clinical Investigation Plans (CIP)

• Updates to Clinical Investigation Reports (CIR)

• Increased scrutiny by ethics committees and authorities

Authorities are expected to directly reference this version when assessing compliance with Good Clinical Practice requirements.

Compliance Actions for Manufacturers and Sponsors

To align with ISO 10993 and ISO 14155:2026 updates, organizations should:

• Reassess biocompatibility evaluation strategies under ISO 10993-6 and -7

• Update toxicological risk assessment methodologies

• Incorporate new annex guidance into test strategies

• Transition clinical investigation procedures to ISO 14155:2026 immediately

• Update QMS documentation, CIP, and CIR templates

• Ensure training of clinical and regulatory teams on new requirements

Internal Resource

EU Medical Device Classification & Regulation (MDR/IVDR)

External Resources

• ISO 10993-6:2026

• ISO 10993-7:2026

• ISO 14155:2026